These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35335877)

  • 1. The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis.
    Song Y; Lim HH; Yee J; Yoon HY; Gwak HS
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
    Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
    J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
    Lehtisalo M; Taskinen S; Tarkiainen EK; Neuvonen M; Viinamäki J; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Backman JT; Tornio A; Niemi M
    Br J Clin Pharmacol; 2023 Jan; 89(1):242-252. PubMed ID: 35942816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.
    Futatsugi A; Toshimoto K; Yoshikado T; Sugiyama Y; Kato Y
    Drug Metab Dispos; 2018 May; 46(5):749-757. PubMed ID: 29440178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study.
    Borić-Bilušić AA; Božina N; Lalić Z; Lovrić M; Nađ-Škegro S; Penezić L; Barišić K; Trkulja V
    Adv Ther; 2023 Feb; 40(2):601-618. PubMed ID: 36434147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
    Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
    Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
    Sun F; Chen Z; Yao P; Weng B; Liu Z; Cheng L
    Front Pharmacol; 2021; 12():641075. PubMed ID: 33762959
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
    Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
    Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of rs2231142 in
    AlAzzeh O; Roman YM
    Pharmacogenomics; 2023 Feb; 24(3):173-182. PubMed ID: 36661065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.
    Soko ND; Chimusa E; Masimirembwa C; Dandara C
    Pharmacogenomics J; 2019 Jun; 19(3):240-248. PubMed ID: 30100615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
    Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
    J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
    Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
    Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
    Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
    Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.